AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05749523 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Exercise vs non-exercise
Study NCT02639975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: once daily oral administration
Study NCT00297856 — intervention group
Intervention type: BIOLOGICAL
Intervention: Boostrix®
Description: Single dose
Study NCT00297856 — intervention group
Intervention type: BIOLOGICAL
Intervention: Td (Tetanus diphtheria) vaccine
Description: Single dose
Study NCT04567030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental monitoring (DM)
Description: DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
Study NCT00557076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar Auditory Sensory Training
Description: Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
Study NCT00557076 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Auditory Sensory Training
Description: The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
Study NCT00321828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
Study NCT00321828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
Study NCT00321828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
Study NCT00321828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
Study NCT02887300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review.
Study NCT00757848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 60 mg, oral tablet, twice daily for 28 days
Study NCT00757848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD9668 Placebo equivalent
Description: Match placebo to 60 mg, oral tablet, twice daily for 28 days
Study NCT01207648 — intervention group
Intervention type: DRUG
Intervention: Rebif®
Description: This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
Study NCT02938403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo counseling
Description: Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
Study NCT02938403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Counseling
Description: Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
Study NCT00506129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
Study NCT00506129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
Study NCT00506129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Transplant
Description: Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
Study NCT00506129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
Study NCT01732874 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Expecta 200 mg
Description: Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
Study NCT01732874 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Expecta 1 gram
Description: Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
Study NCT00061243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine with protein vaccine boost
Description: Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
Study NCT03107143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q2 System
Study NCT01251029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 1200 mg orally; 600mg i.v.
Study NCT01251029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siran (N-acetylcysteine)
Study NCT03728634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-682884
Description: ION-682884 administered SC
Study NCT03728634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator calculated volume to match ION-682884 administered SC
Study NCT03728634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral supplement
Study NCT03728634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: Oral supplement
Study NCT01521416 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated.
Study NCT01431911 — intervention group
Intervention type: DRUG
Intervention: Early maintenance treatment
Description: Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
Study NCT01431911 — intervention group
Intervention type: DRUG
Intervention: Delayed Maintenance treatment
Description: Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
Study NCT02922101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
Study NCT02922101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and Feedback
Description: An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
Study NCT02922101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolbox
Description: A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
Study NCT00026221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: Given SC
Study NCT00026221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT05396131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Sealant
Description: The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
Study NCT05396131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Valve (EBV)
Description: The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
Study NCT05396131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Valve (EBV)
Description: The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
Study NCT03832309 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Do we speak to them in a way that convinces them to have the dream
Description: During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
Study NCT03832309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Do we speak to them in a way that convinces them to have the dream
Description: During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
Study NCT02922946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor
Study NCT03758261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paravertebral nerve block
Description: The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
Study NCT03758261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erector Spinae nerve block
Description: The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
Study NCT01465386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC
Study NCT00134615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RQP patient health education module
Study NCT03725956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice
Study NCT03938051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
Study NCT03938051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: 20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
Study NCT01883700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Pasta
Study NCT01883700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Chickpeas with Oil
Study NCT01883700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant Mashed Potatoes
Study NCT01883700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant Mashed Potatoes with Egg Whites
Study NCT01208792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
Study NCT01208792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected
Study NCT01208792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: a blood sample will be collected
Study NCT00375648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT02412618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Progesterone antagonist
Study NCT02412618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Prostaglandin E1
Study NCT02412618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Prostaglandin E1
Study NCT02412618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tasteless, odorless, sugar based pill
Study NCT01123343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrueVision 3D Visualization and Guidance System for MicroSurgery
Description: Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
Study NCT01399112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based computer program
Description: Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
Study NCT01399112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based computer program
Description: Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
Study NCT02071771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lenses
Study NCT02071771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lenses
Study NCT04144283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAP
Description: For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep.
Study NCT04144283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WAKE
Description: For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
Study NCT02336061 — intervention group
Intervention type: BEHAVIORAL
Intervention: Evaluation of gender differences on the psychosocial and economic impact.
Study NCT01762683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myometrium biopsy and blood samples
Description: The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.
Study NCT01762683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myometrium biopsy and blood samples
Description: The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.
Study NCT02975804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tymo
Description: All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
Study NCT00843336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic hormonal fertility monitoring
Description: Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
Study NCT00843336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring of externally observed cervical mucus to determine level of fertility.
Study NCT01087983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Starting oral dose of 500 mg daily for 21 day cycle.
Study NCT01087983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Starting oral dose 1 mg daily.
Study NCT01087983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Starting oral dose 1000 mg daily.
Study NCT00912626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One week follow up assessment results
Description: FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
Study NCT02248766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: somofilcon A lens
Study NCT02248766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: somofilcon A lens
Study NCT03299309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP-CMV
Description: Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
Study NCT02378883 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo™ Onyx™ Delivery Micro Catheter
Study NCT00881985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: Use CPAP whenever sleep
Study NCT00473889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 400 mg capsules once daily. Up to 6 months of treatment
Study NCT00473889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: paclitaxel
Description: intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
Study NCT02639975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily oral administration
Study NCT00473889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: paclitaxel
Description: intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment